BCR signaling pathway inhibitors such as Syk inhibitors [1] [2] [3] have shown promise in CLL, a mature B cell cancer where the BCR pathway is constitutively active 4 . However, sustained BCR signaling can lead to anergy and apoptosis in a process including IgM downregulation, reduced responsiveness to BCR ligands, high intracellular Ca 2+ and activation of BCR pathway kinases 4, 5 . Several studies suggest that CLL cells are rescued by combined BCR and CD40L triggering; an anti-apoptosis, activation and differentiation signal is mediated by T helper (Th) cells via CD40L (CD40Ligand, CD154) that binds CD40 on the B cell surface [6] [7] [8] [9] [10] . Thus, CLL patients have CLL-specific Th cells that can support CLL cell proliferation in xenografts 8, 9 , activated CD40L + Th cells co-localize with proliferating CLL cells in pseudofollicles 6, 7 , and CLL cells secrete Th attracting chemokines recruiting T cell help 6, 9 . It has been unclear how BCR pathway inhibitors impact the We stimulated CLL cells (Table S1) or normal B cells with CD40L using human CD40L + murine L cell fibroblasts 11 for 6 days and measured proliferation by using the BrdU flow kit (anti-BrdU, 3D4
BD). B cell activation was monitored by CD38 expression on gated CD19 + cells (HB7; HIB19, eBioscience). CD40L + L cells stimulated CLL cell blastogenesis, CD38 expression, generation of CLL cell clusters and proliferation of cells in all patients analyzed ( Figure 1A -C, Supplementary Figure   S1 ). Blastogenesis and cell clustering was dramatically reduced in the presence of the Syk inhibitor fostamatnib (R406), Figure 1B . Nevertheless, CLL cells were viable and activated as indicated by the expression of the activation marker CD38 ( Figure 1C, Supplementary Figure S1 ). In contrast, both the blastogenesis (9 of 10 patients) and proliferation responses (10 of 10 patients) were inhibited in CLL cells ( Figure 1D ). We extended the analysis to P505-15, a novel and highly selective Syk-inhibitor 2 .
P505-15 inhibited blastogenesis and CLL proliferation ( Figure 1D , bottom panel). Remarkably, normal B cells (purified from healthy donors by negative selection kit, Miltenyi) were not inhibited in these assays ( Figure 1E ).
We proceeded to investigate pathway activation with phosphoflow analyses; samples were prepared using phosphoflow reagents from BD Biosciences (San Jose, CA, USA). Permeabilized cells were barcoded with combinations of esters conjugated to Pacific Blue, Alexa Fluor 488 or Pacific Orange (Molecular Probes/Life Technologies) washed and pooled as described 12 . CD19 + barcoded cells (PECy7, SJ25C1, BD Bioscience) were stained with Alexa Fluor 647-conjuated phospho-specific antibodies and acquired on a FACSCanto II, and analyzed as described 12 .
In agreement with previous reports 4 Observation time, treatment-free months since diagnosis. Non-treated patients are marked with Not T. Treated patients have received regimens with the following drugs marked with abbreviations: F= Fludarabine; C = Cyclophosphamide; A=Alemtuzumab; R=Rituximab; BR=bendamustine. Cells were gathered before treatment except for CLL126 and CLL135. Patient CLL126 was initially treated with F, thereafter with FC, then FCR (aborted due to toxicity), and replaced by A monotherapy. Samples for CLL126 were gathered prior to FCR treatment. Patient CLL135 was initially treated with FCR, then A and finally BR. Samples were gathered between 2nd and 3rd treatment.
